Seres Therapeutics (NASDAQ:MCRB) Receives "Sell (D+)" Rating from Weiss Ratings

Key Points

• Seres Therapeutics has received a "Sell (D+)" rating from Weiss Ratings, which was reaffirmed in a recent research report.
• Canaccord Genuity Group raised the price target for Seres Therapeutics from $14.00 to $22.00, assigning it a "buy" rating.
• The stock has a current average price target of $14.33, with a consensus rating of "Reduce" among analysts.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report)'s stock had its "sell (d+)" rating reiterated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Canaccord Genuity Group increased their price target on shares of Seres Therapeutics from $14.00 to $22.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $14.33.

Seres Therapeutics Price Performance

Shares of Seres Therapeutics stock opened at $19.64 on Wednesday. The company has a 50-day moving average of $17.82 and a 200 day moving average of $12.76. The firm has a market cap of $171.85 million, a price-to-earnings ratio of -4.27 and a beta of 0.19. Seres Therapeutics has a 1 year low of $6.53 and a 1 year high of $24.67.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.72) by $0.45. On average, equities analysts anticipate that Seres Therapeutics will post -0.38 EPS for the current year.

Institutional Trading of Seres Therapeutics

Several institutional investors have recently bought and sold shares of MCRB. SBI Securities Co. Ltd. grew its position in Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 48,013 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 21,679 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 89,995 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Seres Therapeutics during the 2nd quarter valued at about $249,000. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock valued at $760,000 after acquiring an additional 147,671 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.